longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

GRI Bio

GRI

1.8500.54% ( +0.010 )
Trading: Sep 18, 13:37:07 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Silicon Valley’s Desperation and the Real Economy’s Revenge

    Global Report·Sep 15 at 10:12 AM
    GRI-0.54%KURA+0.34%
  • GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

    Unusual Whales·Sep 8 at 12:16 PM
    GRI-0.54%
  • GRI Bio says Phase 2a trial shows GRI-0621 lifts placebo-adjusted FVC in IPF patients at 12 weeks

    PUBT·Sep 8 at 12:16 PM
    GRI-0.54%
  • Commercial Milestones and AI Tailwinds: Key Shifts Across Niche Players This Week

    Global Report·Sep 8 at 11:33 AM
    LWLG-0.90%VECO+1.74%
  • Cut the Hype: In 2026, Wall Street is Only Paying for Hard AI Infrastructure and Weight-Loss Miracles

    Global Report·Sep 8 at 09:19 AM
    YSXT+8.40%SDGR-5.13%
  • GRI Bio highlights IPF drug candidate GRI-0621 in “Why Now” webcast ahead of ERS 2026 data presentation

    PUBT·Aug 27 at 01:02 PM
    GRI-0.54%
  • GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 | GRI Stock News

    StockTitan·Aug 24 at 05:05 AM
    GRI-0.54%
  • GRI Bio, Inc. 2Q 2026: Net income $(1.64) M, EPS $(0.91) — 10-Q Summary

    TradingView·Aug 14 at 11:51 AM
    GRI-0.54%
  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

    benzinga_article·Aug 11 at 05:06 PM
    ALMR+6.15%GRI-0.54%
  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

    benzinga_article·Jul 20 at 12:05 PM
    BRNS0.00%VBIO-0.90%
  • GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis | GRI Stock News

    StockTitan·Jun 18 at 04:31 AM
    GRI-0.54%